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Abstract  
BACKGROUND: Bladder cancer represents the fifth most common malignancy worldwide and a major cause of 
cancer-related morbidity and death. Incidence and mortality rates have remained relatively constant over the past 
four decades. Urothelial bladder cancers have identified multiple risk factors.  
AIM: We aimed at evaluating the expression of the FGFR3 protein and gene amplification in the urothelial cells of 
neoplastic and non-neoplastic urothelial lesions of the urinary bladder, and correlation with tumour grade, stage 
and associated bilharziasis. 
 
MATERIAL AND METHODS: One hundred and five different urinary bladder lesions were studied, including 15 
cystitis cases (9 bilharzial and 6 non-bilharzial cystitides), 75 urothelial carcinoma cases (18 bilharzial associated 
and 57 non-bilharzial associated) and 15 squamous cell carcinoma associated with bilharziasis, beside 5 control 
cases. Data concerning age, sex, tumour grade, stage, and associated bilharziasis were obtained. Each case was 
studied for FGFR3 expression, and FISH technique was applied on forty malignant cases that show high protein 
expression. 
 
RESULTS: The highest incidence of cystitis was in the fourth decade while of bladder cancer was in the seventh 
decade. Tumour grade was correlated significantly with tumour stage. FGFR3 correlates significantly with tumour 
grade, stage and with a bilharzial infestation. FGFR3 gene amplification was reported mainly in low grade and 
NNMBIC tumours. 
 
CONCLUSIONS: FGFR3 overexpression in malignant cases was significantly higher than in chronic cystitis. 
FGFR3 gene amplification was reported mainly in low grade and NNMBIC tumours. FGFR3 may be further 
studied as a subject for target therapy of bladder cancer. 
 
 
 
 
 
Introduction 
 
In Egypt, bladder cancer accounts for about 
30% of all cancers, with many pathogenic factors 
most commonly schistosomal infestation, which is an 
endemic disease in Nile River area [1]. In areas where 
schistosomiasis is endemic there is a high incidence 
of squamous cell carcinoma of the urinary bladder. 
Schistosomiasis causes chronic granulomatous 
cystitis leading to squamous metaplasia of transitional 
epithelium, and subsequently development of 
squamous cell carcinoma [2]. Transitional cell 
carcinoma is the most common type of bladder 
cancer. It arises primarily from transitional cells of 
bladder mucosal epithelium and may be present as 
non-invasive papillary or non-papillary tumours [3].  
The interaction between transitional cell 
carcinoma cells and the adjacent or underlying 
bladder stroma may be an important determinant in 
the progression of superficial to invasive disease [4]. 
Fibroblast growth factors (FGFs) orchestrate a variety 
of cellular functions by binding to their trans-
membrane tyrosine-kinase receptors (FGFRs) and 
activating downstream signalling pathways, including 
RAS/MAPK, PLCγ1, PI3K, and STATs [5]. Fibroblast 
growth factor receptor three signalling is altered in a 
high proportion of bladder tumours. Activating 
mutations and overexpression of FGFR3 are common 
in urothelial tumours with low malignant potential and 
low-stage and -grade urothelial carcinomas and are 
associated with a lower risk of progression and better 
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survival in some subgroups [5]. FGFR3 mutations are 
linked to favourable (low grade/stage) pTa bladder 
cancer [6]. Fibroblast Growth Factor receptor 3 
(FGFR3) mutations are most common in low-risk 
NMIBC (non-muscle invasive bladder cancer), a 
subset of MIBC (muscle invasive bladder cancer) that 
carries FGFR3 mutations shows particularly poor 
prognosis [7]. Foth et al., [7] stated that FGFR3 
activation leads to urothelial cell abnormalities in the 
absence of Pten gene. The fgfr3 expression is present 
in both primary and metastatic urothelial cancer, and 
the majority of metastases retain immmunohisto-
chemical expression of FGFR3 if it was expressed in 
the primary tumour [8]. Subsequent larger studies 
established that FGFR3 mutations occur in around 
50% of both lower and upper urinary tract tumours 
and these cluster in three distinct hotspots in exons 7, 
10, and 15 [6,9]. FGFR3 mutations are thought to 
induce a conformational change in the kinase domain 
resulting in ligand-independent receptor activation and 
signalling; they have also been shown to alter FGFR3 
cellular localisation, inducing aberrant signalling from 
the endoplasmic reticulum [10].  
FGFR3 mutation status was the strongest 
predictor of recurrence when compared with stage 
and grade. This is the first mutation in bladder cancer 
that selectively identifies patients with favourable 
disease characteristics [11].While FGFR3 mutation or 
copy number gain is a rare event, studies of these 
tumours may shed light on how FGFR3 signalling 
contributes to urothelial carcinoma growth and 
proliferation [8]. Furthermore, based on preclinical 
studies that suggest the FGFR pathway, and 
specifically FGFR3, may be a valid therapeutic target, 
we believe this area of investigation warrants further 
exploration [8]. In vitro and in vivo studies have shown 
that FGFR inhibition has cytotoxic and cytostatic 
effects in FGFR-dependent bladder cancer cells and 
FGFR-targeted agents are currently being 
investigated in clinical studies for the treatment of 
urothelial carcinoma [5]. Overall, FGFRs hold promise 
as therapeutic targets, diagnostic and prognostic 
markers, and screening tools for early detection and 
clinical management of urothelial carcinoma [5].  
In our study, we are aiming to evaluate the 
association of FGFR3 expression and gene mutation 
and its risk in the development of urothelial carcinoma 
(bilharzial and non-bilharzial), the effect on grading 
and staging of the tumour and the benefit of using this 
marker as a therapeutic target and diagnostic tool in 
bladder cancer patients.
 
 
 
Patients and Methods 
 
The material of this study included 110 
formalin fixed paraffin embedded (FFPE) biopsies. 
The cases were included according to the following 
criteria:  
Inclusion criteria: Adult Cases with bladder 
cancer; with different grades and stages; with or 
without bilharzial cystitis; nature of the specimen: 
TUR-T or radical cystectomy;  
Exclusion criteria: receiving chemotherapy 
and radiotherapy; children. 
 
Groups 
According to [12-13], the 110 cases were 
categorised into the following groups: 
 
Group (1): Control; 5 cases. These cases 
were (4 males and 1 female with age range 20–46 y) 
with normal, healthy urothelium, and served as 
controls undergoing cystoscopy for other reasons than 
lower urinary tract symptoms, such as ureteroscopy or 
ureteric catheter or double J-insertion and biopsies 
were taken upon their consent. 
Group (2): Cystitis: a) Bilharzial cystitis, 9 
cases; b) Non-Bilharzial cystitis, 6 cases. 
 
Group (3): Urothelial (Transitional cell) 
carcinoma: n= 75 cases. A) Bilharzial Transitional cell 
carcinoma (Bil.TCC), 18 cases; b) Non Bilharzial 
Transitional cell carcinoma (TCC), 57 cases.  
Group (4): Squamous cell carcinoma: 15 
cases. A) Bilharzial Squamous cell carcinoma (Bil 
SqCC), 15 cases; Obtained from the archives of 
Pathology Departments of Theodor Bilharz Research 
Institute (TBRI). 
 
Histopathological grading and staging 
According to Histopathological grading and 
staging, bladder cancer was categorized into:  
a- Histopathological grading: 1- Low grade 
transitional cell carcinoma (n = 28); 2- High grade 
transitional cell carcinoma (n = 47); 3- High grade 
squamous cell carcinoma (n = 15).   
b- Histopathological staging: 1- NMIBC 
(superficial tumors transitional cell carcinoma (n = 45); 
2- MIBC transitional cell carcinoma (n = 30); 3- SCC 
cases were MIBC (n = 15).  
 
The personal and clinical data 
For each case: A) The personal and clinical 
data were obtained from the patient’s records 
(including age and sex); B) Four-μm sections were 
prepared from the paraffin block and stained as 
follows: Hematoxylin and Eosin stain; 
Immunohistochemical stain against FGFR3; and 
Fluorescent in Situ Hybridization for FGFR3 (for 
malignant cases only).  
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Photomicrography 
Photomicrographs included in this study were 
captured by AxioCam MRc5 camera mounted to Zeiss 
Scope A1 Microscope.  
 
Immunohistochemical procedure  
Immunohistochemistry for FGFR3 was 
performed on sections cut from the paraffin blocks 
with a commercially available rabbit monoclonal Anti-
FGFR3 antibody (sc-13121, Santa Cruz, USA). Slides 
were sectioned at 4μm onto positively charged slides 
(Superfrost Plus, Menzel-Glaser, Germany) and the 
slides were stained on an automated platform the 
(Dako Autostainer Link 48). Heat-induced antigen 
retrieval was used for 30 min at 97°C in the high-PH 
EnVision™ FLEX Target Retrieval Solution, and the 
primary antibody was used at a dilution of 1 in 100. 
The detailed histopathological assessment was done 
regarding confirmation of diagnosis and grading of 
malignant cases. 
 
Immunohistochemical assessment was done 
according to [9]. Cells with membrane cytoplasmic 
staining were considered positive: The intensity and 
extent of cells stained positively for FGFR3 was 
evaluated by assessing 10 high-power microscopic 
fields by two independent pathologists (OH &TA): 
*Score 0: All tumor cells are negative; *Score +1: 
Weak but detectable positivity in some or all cells; 
*Score +2: moderate but extensive positivity; and 
*Score +3: strong positivity (regardless of extent).  
 
Fluorescence in situ hybridization (FISH) 
technique  
The probe contains green-labeled 
polynucleotides (Zygreen) which target FGFR3 gene 
and orange-labeled polynucleotides which target 
sequences of chromosome 4 in the chromosomal 
region 4p11. The code number of the used probe is 
(ZytoLight ® SPEC FGFR3/4p11 Dual Color Probe, 
Previously: ZytoLight SPEC FGFR3/CEN 4 Dual Color 
Probe).  
Sections were de-waxed, then incubated for 
10 minutes at 70% on a hot plate, followed by 
incubation for 2x 10 minutes in xylene then rehydrated 
in 100%, 100%, 90%, and 70% ethanol, each for 5 
minutes and lastly washed 2x2 minutes in distilled 
water. Sections were incubated for 15 minutes in pre-
warmed Heat Pretreatment Solution Citric at 98, then 
transferred immediately to distilled water, washed for 
2x2 minutes and water was drained off. Pepsin 
solution was applied to tissue sections that were 
incubated for 10 minutes at 37 in a humidity chamber. 
After that, sections were washed for 5 minutes in 
Wash Buffer SSC and 1 minute in distilled water. The 
following steps were then successively done: 
Dehydration in 70%, 90%, and 100% ethanol, each for 
1 minute. Air dry sections then, pipette 10μl Zytolight 
FISH probe each onto individual samples. Cover the 
samples with a coverslip (with hot glue from an 
adhesive pistol). Denature the slides at 75 ºC for 10 
minutes on a hot plate. Transfer the sections to a 
humidity chamber and hybridise overnight at 37ºC. 
Remove the glue carefully and remove the coverslip 
by submerging in 1x Wash Buffer for 2x5 minutes at 
37 ºC for 1-3 minutes. Incubate the slides in 
70%.90%, and 100% each for one minute. 
 
Air dry samples protected from light. Cell 
nuclei were stained by pipetting 30μl DAP/Dura-Tect-
solution onto the sections. Avoiding trapped bubbles 
cover the samples with a coverslip. Carefully remove 
excess DAP/Dura-1-solution by gently pressing the 
slide between filter papers. Store the slides in the 
dark. For longer storage periods; this should take 
place at 2-8C. Evaluation of the sample material; is 
carried out by Fluorescence microscopy.  
 
Interpretation of FISH 
Evaluation of the FGFR3 gene is carried out 
by fluorescence microscopy (Olympus X51) [using 
three filters red (FITC), green, and DAPI] using a × 
1000 oil immersion objective lens. The microscope is 
attached to a high-resolution video camera (Jale) and 
monitor. We captured and interpreted photos using 
hardware (Cytovision 2.3, USA).
 
SPEC FGFR3 Dual Color Probe hybridized to 
normal interphase as indicated by two orange/green 
fusion signals per nucleus no amplification of 
Fibroblast growth factor receptor 3 (FGFR3), SPEC 
FGFR3 Dual Color Probe hybridized with interphase 
cells showing an over expression of chromosome 4 as 
indicated by multiple green more than orange signals 
in the nuclei according to [14]. 
 
Statistical analysis  
SPSS software version 18 was used for data 
management and analysis. Quantitative data were 
presented as mean ± SD. Qualitative data were 
presented as frequencies and percentages. To study 
the relationship between variables, Spearman’s 
correlation coefficient was calculated. Tests were 
considered statistically significant when P< 0.05. 
 
 
Results 
 
Sex distribution in different lesions 
studied 
Urothelial lesions were more predominated in 
males; as 12 out of 15 cases (80%) with chronic 
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cystitis, 11 out of 15 cases with squamous cell 
carcinoma (73%) and 49 out of 75 cases with 
transitional cell carcinoma (65%) were males. The 
highest frequency of urothelial carcinomas was in the 
seventh decade (51.2%) (Table 1). 
Table 1: Age distribution among patients studied 
Decade  
Cystitis  Malignant 
Total No % 
No % No % 
21-30 4 40% 0 0 4 7.2% 
31-40 5 50% 1 2.3% 6 10.9% 
41-50 1 10% 4 8.9% 5 9.1% 
51-60 0 0 15 33.3% 15 27.3% 
61-70 0 0 23 51.2% 23 41.8% 
71-80 0 0 2 4.5% 2 3.7% 
Total 10 100% 45 100% 55 100% 
 
 
Extent and Intensity of FGFR3 expression 
in studied cases by IHC 
  FGFR3 immunoexpression was 
demonstrated as membrane-cytoplasmic staining of 
urothelial cells. In control, all cases were negative for 
FGFR3 immunostaining. In the chronic cystitis group, 
10 cases out of 15 cases (66.6%) were positive for 
FGFR3 immunostaining; eight cases with mild 
intensity and two cases with moderate intensity. 
 
Table 2: Extent and Intensity of FGFR3 expression in studied 
cases 
Item 
Positive cases 
Mean % of 
positive cells 
± SD 
Intensity of FGER immunostaining 
Mild Moderate Marked 
No %  No % No % No % 
Control n=5 0 0 0 0 0 0 0 0 0 
Chronic cystitis 
n=15 
10 66.6% 22 ± 30.8 8 53% 2 13% 0 0 
Non – Bilharzial 
cystitis, n=6 
4 66.6% 8.4 ± 7.6 4 66.6% 0 0 0 0 
Bilharzial cystitis 
 n=9 
6 66.6% 31.2 ± 37.3
(b)
 4 44.5% 2 22.5% 0 0 
Malignant n=90 61 67.8% 38.5 ± 31.8
(a) 
33 36% 19 21% 9 10% 
Non – Bilharzial 
carcinomas n=57 
43 75.4% 43.6 ± 30.4
 
21 36.8%  14 24.5% 8 14% 
Bilharzial 
carcinomas n=33 
18 54.5% 30.9 ± 32.8
  
12 36.3% 5 15.2% 1 3.1% 
a) p-value < 0.01 compared to chronic cystitis cases; b) p-value < 0.01 compared to non-
bilharzial carcinoma cases. 
 
 In the malignant group; 61 out of 90 cases 
(67.8%) were positive for FGFR3 immunostaining; 
thirty-three cases were of mild intensity, 19 cases 
were of moderate intensity, and 9 cases were of 
marked intensity. There was a significant difference 
between malignant group and control group at p-value 
<0.01 (Table 2; Fig. 1: A-D).  
 Seventy-two percent of TCC cases were 
positive for FGFR3 by immunostaining with mild, 
moderate, and marked staining (38.6%, 21.4% and 
12%) respectively. Seven cases out of 15 squamous 
cell carcinoma cases (46.7%) were positive for 
FGFR3 expression with mild and moderate 
immunostaining in 26.7% and 20% respectively (Table 
3). There was a significant inverse correlation 
between the score of expression and both the stage 
and the grade of malignancy (p<0.05 and p<0.01 
respectively) (Table 4; Fig. 1: E-H).
 
 
Figure 1: (A) Case of bilharzial cystitis with proliferative changes( 
Brunn`s nests) and calcified bilharzial ova (H&E, X 100); (B) Case 
of Papillary urothelial carcinoma low grade , not invading lamina 
(Ta) (H&Ex50); (C) Case of urothelial carcinoma high grade, 
invading lamina and muscle layer (T2) associated with bilharziasis 
(H&E x200); (D) Case of Squamous cell carcinoma with calcified 
bilharzial ova, high grade, invading lamina and muscle layer (T2) 
(H&E x200); (E) Case of cystitis, negative for FGFR3 
immunostaining (IHC, DAB, x100); (F) Case of papillary urothelial 
carcinoma low grade, not infiltrating lamina Ta, strongly positive for 
FGFR3 immunostaining. (IHC, DAB, x100); (G) Case of a case of 
urothelial carcinoma high grade, infiltrating lamina and muscle layer 
T2, positive cytoplasmic for FGFR3 immunostaining, mild intensity 
(IHC, DAB, x200); (H) Case of squamous cell carcinoma high-
grade, malignant cells show positive cytoplasmic for FGFR3 
immunostaining, mild intensity. (IHC, DAB, x200) 
  
FGFR3 expression by FISH 
The fish technique was applied to forty cases 
in a malignant group with overexpression of the 
FGFR3 protein. 36 malignant cases out of 40 cases 
show amplified FGFR3 gene. Positive malignant 
cases show a significant difference compared to 
negative cases at p-value <0.01. Most of the positive 
cases were of low grade (55.5%) and showed a 
significant difference at p-value < 0.01 compared to 
high grade. In NMIBC group (77.7%) there was a 
statistical difference at p-value 0.01 compared to 
MIBC group.
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Table 3: Extent and intensity of FGFR3 Expression in different 
malignant cases about tumour grades and stages
 
Carcinoma  
Number of 
positive 
cases 
Mean % of 
positive 
cells ± S.D. 
Intensity of FGFR3 immunostaining 
Mild Moderate Marked 
No % No % No % 
Transitional cell 
carcinoma n=75 
54 72% 40.5±30 29 38.6% 16 21.4% 9 12% 
Superficial 
Tumours 
(NMIBC)TCC
 
n=45 
40 88.8% 52.4±26.2 18 40% 15 33.3% 7 15.6% 
Muscle invasive in 
TCC 
n=30 
14 46.7% 22.6±28.5
(a)
 11 78.5% 1 7.2% 2 14.2% 
Low grade 
Tumors TCC 
n=28 
26 92.8% 58.5±22 9 32.2% 11 39.2% 6 21.4% 
High Grade 
Tumors in TCC 
 n=47 
28 59.5% 29.7±30.2
(b)
 20 71.4% 5 17.8% 3 10.7% 
Squamous cell 
carcinoma  
n=15 
7 46.7% 31.3±36 4 26.7% 3 20% 0 0 
Superficial 
Tumors (NMIBC) 
in scc 
n=0 
0 0 0 0 0 0 0 0 0 
Muscle invasive 
Tumors in scc 
n=15 
7 46.7% 31.3±36.8 4 26.7% 3 20% 0 0 
Low Grade SCC 
N=0 
0 0 0 0 0 0 0 0 
 
0 
High-Grade SCC 
N=15
 
7 46.7% 31.3±36.8 4 26.7% 3 20% 0 0 
(a) A significant difference between NMIBC and Invasive bladder cancer of TCC type; (b) 
Significant difference between low-grade tumours and high-grade tumours at p-value 
<0.05 compared to low grade.
 
 
A total of 88.2% of TCC cases showed 
FGFR3 gene amplification; mostly were of low grade 
(70%) and showed a significant difference at p-value < 
0.01 compared to high grade. In NMIBC group (80%) 
there is a statistical difference of FGFR3 gene 
amplification at p-value 0.01 compared to MIBC 
group. 
 
Table 4: Correlation between FGFR3 parameters and grade and 
stage of malignancy: 
 Grade Stage Score Positive 
Spearman's rho 
Grade 
Correlation 
Coefficient 
1.000 0.479
**
 -0.416
**
 -0.064 
Sig. (2-tailed) . 0.001 0.003 0.656 
N 50 46 50 50 
Stage 
Correlation 
Coefficient 
0.479
**
 1.000 -0.233 -0.035 
Sig. (2-tailed) 0.001 . 0.047* 0.798 
N 46 55 55 55 
Score 
Correlation 
Coefficient 
-0.416
**
 -0.233 1.000 0.378
**
 
Sig. (2-tailed) 0.003 0.047* . 0.002 
N 50 55 62 62 
Positive 
Correlation 
Coefficient 
-0.064 -0.035 0.378
**
 1.000 
Sig. (2-tailed) 0.656 0.798 0.002 . 
N 50 55 62 62 
*. Correlation is significant at the 0.05 level (2-tailed); **. Correlation is significant at the 
0.01 level (2-tailed). 
 
While all cases of SCC have FGFR3 gene 
amplification, most of the positive cases were of high 
grade and belong to the MIBC group (83.3%) with a 
significant difference at p-value < 0.01 compared to 
high grade and NMIBC group. Almost all cases of 
SCC and TCC associated with bilharziasis report 
FGFR3 gene amplification with a significant difference 
between TCC on bilharzial compared to TCC 
bilharzial groups at P value < 0.05 (Table 5). 
 
Figure 2: (A) SPEC FGFR3 Dual Color Probe hybridized to normal 
interphase as indicated by two orange/green fusion signals per 
nucleus from a case of TCC Ta GI showing malignant cells with 
normal expression, no amplification of Fibroblast growth factor 
receptor 3 (FGFR3) as two FGFR3 signals (green) and two 
chromosome 4 signal (orange/red) (red arrows) (FISH, 
magnification ×1000); (B) Urinary bladder tissue from a case of 
SCC, SPEC FGFR3 Dual Color Probe hybridized with interphase 
cells showing polysomy of chromosome 4 as indicated by multiple 
green and orange signals in the nuclei (magnification ×1000); (C) 
Urinary bladder tissue from a case of SCC, SPEC FGFR3 Dual 
Color Probe hybridized with interphase cells showing an 
amplification of the FGFR3 gene (green signals) 
(magnification×1000); (D) Urinary bladder tissue from a case of 
TCC T1 GII, SPEC FGFR3 Dual Color Probe hybridized with 
interphase cells showing polysomy of chromosome 4 as indicated 
by multiple green and orange signals in the nuclei 
(magnification×1000); (E) Urinary bladder tissue from a case of 
TCC T1 GII, SPEC FGFR3 Dual Color Probe hybridized with 
interphase cells showing an amplification of the FGFR3 gene 
(green signals) (magnification×1000) 
 
Amplified FGFR3 gene was documented in 
90% of malignant cases with mild FGFR3 staining 
intensity and 84.6% of positive malignant cases with 
moderate staining intensity showing a significant 
difference compared to the negative malignant cases 
with moderate intensity at p-value < 0.01. 
 
Amplified FGFR3 gene was reported in 85.7% 
of low-grade tumours with marked staining intensity 
showing a significant difference compared to the high-
grade tumours at p-value < 0.01. Amplified FGFR3 
gene was also reported in 92.3% in NMIBC with 
moderate staining intensity showing a significant 
difference compared to MIBC group at P value < 0.01 
(Table 6; Fig. 2: A-D). 
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Table 5: FGFR3 gene amplification by FISH technique in 
different studied groups  
Group  
Positive Negative 
P value 
No % No % 
Malignant cases n=40 36 90% 4 10% p<0.01 
Grade  
Low  
High 
 
20 
16 
 
55.5% 
45.5% 
 
2 
2 
 
50% 
50% 
 
p<0.05 
Stage 
NMIBC  
MIBC  
 
28 
8 
 
77.7% 
22.2% 
 
1 
3 
 
25% 
75% 
 
p<0.01 
TCC n=34 30 88.2% 4 11.8% p<0.01 
TCC bIlharzial n=7 7 100% 0 0  
p<0.05 TCC non Bilharzial n=27 23 85.2%* 4 14.8% 
SCC n= 6 6 100% 0 0 p<0.01 
TCC 
Low grade 
High grade  
21 
9 
70% 
30% 
2 
2 
50% 
50% 
p<0.01 
SCC n=6 
Low grade 
High grade  
 
1 
5 
 
16.7% 
83.3% 
 
0 
 
0 
 
p<0.01 
TCC n=34 
NMIBC  
MIBC  
 
24 
6 
 
80% 
20% 
 
3 
1 
 
75% 
25% 
 
p<0.01 
Scc n=6 
NMIBC 
MIBC  
 
1 
5 
 
16.7% 
83.3% 
 
0 
0 
 
0 
0 
 
p<0.01 
There are 36 malignant cases out of 40 cases show amplified FGFER3 gene, most of the 
positive cases were of low grade (55%) and were in NMIBC group (72.5%).There were 
88.2% of TCC cases show FGFR3 gene amplification   most were of LOW grade (61.8%)  
and were in NMIBC group  (82.4%) while all cases of  SCC  have FGFR3 gene 
amplification most of the positive cases were of high grade (83.3%) and  MIBC (82.4%). 
 
 
 
Discussion 
 
Schistosomiasis is not known to be 
associated with any malignant disease other than 
bladder cancer. In Egypt, the frequency rate of the 
bladder cancer has declined significantly during the 
last 25 years. This drop is mainly related to the control 
of schistosomiasis [15]. In the present work, the 
incidence of bilharzial infestation in malignant studied 
cases was about 40%, and this was close to what was 
mentioned by Abdulamir et al. [16]. Also, all cases of 
SCC were associated with bilharzial affection and this 
in agreement with [17] who stated that Schistosoma 
infection-induced urinary bladder carcinogenesis and 
also in agreement with Khaled et al. [15] who stated 
that bladder cancer associated with schistosomal 
infection has a high occurrence of SCC type. 
 
Table 6: FGFR3gene amplification by FISH technique in 
malignant cases with different staining intensities  
FGFR3  
Intensity  
Negative Positive NMIBC MIBC Low Grade High Grade 
No % No % No % No % No % No % 
Mild 
n=20 
2 10% 18 90% 10 50% 10 50% 8 40% 12 60% 
Moderate 
n=13 
2 15.4% 11 84.6%** 12 92.3% 1 7.7%* 9 69.2% 4 30.8%* 
Marked  
n=7 
0 0 7 100% 6 85.7% 1 14.3% 6 85.7% 1 14.3%* 
*p < 0.01compared Mild intensity. **p < 0.05compared Marked intensity. 
 
We found that FGFR3 expression was 
negative in control group and this finding is compatible 
Gust et al. [18]. There was no evidence of such 
staining in normal urothelium. We also found that 72 
% of malignant cases were positive for FGFR3 
immunostaining, which is compatible with  Junker et 
al. [19] who stated that expression of FGFR3 was 
found in approximately 70% of both low and high-
grade tumours, as well as equally distributed between 
invasive and non-invasive urothelial carcinoma. 
 
In our study, 88% of urothelial carcinoma 
cases positive for FGFR3 immunostaining were 
superficial non-invasive tumours. A recent study done 
on 255 primary urothelial carcinomas reported that 
63.5 % of superficial carcinoma were positive for 
FGFR3 protein expression by immunophenotyping, 
while only 33% of invasive muscle tumours were 
positive [20].  
About 92 % of low-grade urothelial cancers of 
our cases were positive for FGFR3 immunostaining, 
and this is compatible with Poyet at al. [20] who found 
that 69.4% of low-grade urothelial carcinoma were 
positive to FGFR3, while only 26.7% of high-grade 
tumours were positive for FGFR3. We also reported 
that all cases of SCC were of high grade and with 
muscle invasion and this was in agreement with 
Abdulamir et al. [16] and Salim et al. [17]. About half 
of the SCC cases in the present study were positive 
for FGFR3 immunostaining, and this was also 
explained by Salim et al. [17] who stated that SCC 
showed a predisposition to a high level of FGFR3 
protein expression and mutation. The fish technique 
was applied to forty malignant cases with FGFR3 
protein overexpression to detect gene amplification of 
FGFR3. We found that 36 cases out of 40 cases of 
malignancy (90%) were positive, which is close to 
Tomlinson et al. [9] who mentioned that an 
association between expression level and mutation 
status. Fifty-five percent of positive cases were of low 
grade, and 77.7% were in NMIBC group. This result is 
close to what was reported by Junker et al. [19] who 
stated that 63% of NMBIC group and 59% were at 
low-grade show FGFR3 gene amplification. 
 
We found positivity for FGFR3gene 
amplification in almost all bilharziasis associated 
malignant cases (SCC and TCC). All cases of 
bilharziasis associated SCC cases showed FGFR3 
gene amplification. They were mostly of high grade 
and were in MIBC group. This was previously 
mentioned by Khaled et al. [15] who explained that by 
chromosomal alterations that characterise 
schistosomal bladder cancer cases. FGFR3 point 
mutations, overexpression of FGFR3 protein has been 
described. Although this overexpression was 
associated strongly with the presence of FGFR3 
mutations (up to 85% of FGFR3-mutated tumours 
show strong FGFR3 protein expression), FGFR3 
overexpression was also found in 40% of tumours 
with wild-type FGFR3, particularly in those with an 
invasive phenotype [9, 21].
 
We detected FGFR3 gene amplification in 
88.2% of the TCC cases; about 70% were of low 
grade, and 80% were in NMIBC group. Amplified 
FGFR3 gene was documented in 90% of malignant 
cases with mild FGFR3 staining intensity; in 84.6% 
with moderate staining intensity and in all cases with 
marked staining intensity. Similar results were also 
achieved by Tomilinson et al. [9] who stated that there 
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is an association between expression level and 
mutation status also Fischbach et al. [22] found in 
their study all FGFR3amplified samples showed 
concomitant FGFR3 mutations and FGFR3 protein 
overexpression.  
In conclusion, our findings suggest that 
invasive tumours may develop either from carcinoma 
in situ or Ta cases having multiple genetic alterations 
together including gene amplifications in bilharzial 
associated carcinomas. Estimation of FGFR3 
expression could serve as a prognostic indicator in the 
follow-up of cancer bladder patients along surgical or 
therapy managements, especially in bilharzial 
associated malignant cases. Expression of FGFR3 
could also be utilised for molecular targeted therapy in 
urinary bladder cancer, so, we need further studies to 
target these molecular markers to outline an effective 
treatment strategy for the bladder cancer shortly. 
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